Economic impact of the clinical benefits of bariatric surgery in diabetes patients with BMI ≥35 kg/m²

Obesity (Silver Spring). 2011 Mar;19(3):581-7. doi: 10.1038/oby.2010.199. Epub 2010 Sep 9.

Abstract

The medical costs for a type 2 diabetes patient are two to four times greater than the costs for a patient without diabetes. Bariatric surgery is the most effective weight-loss therapy and has marked therapeutic effects on diabetes. We estimate the economic effect of the clinical benefits of bariatric surgery for diabetes patients with BMI ≥ 35 kg/m². Using an administrative claims database of privately insured patients covering 8.5 million lives 1999-2007, we identify obese patients with diabetes, aged 18-65 years, who were treated with bariatric surgery identified using Healthcare Common Procedure Coding System codes. These patients were matched with nonsurgery control patients on demographic factors, comorbidities, and health-care costs. The overall return on investment (RoI) associated with bariatric surgery was calculated using multivariate analysis. Surgery and control patients were compared postindex with respect to diagnostic claims for diabetes, diabetes medication claims, and adjusted diabetes medication and supply costs. Surgery costs were fully recovered after 26 months for laparoscopic surgery. At month 6, 28% of surgery patients had a diabetes diagnosis, compared to 74% of control patients (P < 0.001). Among preindex insulin users, insulin use dropped to 43% by month 3 for surgery patients, vs. 84% for controls (P < 0.001). By month 1, medication and supply costs were significantly lower for surgery patients (P < 0.001). The therapeutic benefits of bariatric surgery on diabetes translate into considerable economic benefits. These data suggest that surgical therapy is clinically more effective and ultimately less expensive than standard therapy for diabetes patients with BMI ≥ 35 kg/m².

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Bariatric Surgery / economics*
  • Body Mass Index
  • Case-Control Studies
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / economics*
  • Diabetes Mellitus, Type 2 / surgery
  • Female
  • Health Care Costs*
  • Humans
  • Hypoglycemic Agents / economics
  • Hypoglycemic Agents / therapeutic use
  • Insulin / economics
  • Insulin / therapeutic use
  • Middle Aged
  • Multivariate Analysis
  • Obesity / complications
  • Obesity / economics*
  • Obesity / surgery
  • Young Adult

Substances

  • Hypoglycemic Agents
  • Insulin